EICHOR
● Completed
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration · Sponsor: Apellis Pharmaceuticals, Inc.
About this study
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (175)
| Retinal Research Institue, LLC | Phoenix, Arizona, United States | — |
| Associated Retina Consultants, Ltd. | Phoenix, Arizona, United States | — |
| California Retina Consultants | Bakersfield, California, United States | — |
| Retinal Diagnostic Center | Campbell, California, United States | — |
| The Retina Partners | Encino, California, United States | — |
| Retina Consultants of Orange County | Fullerton, California, United States | — |
| Atlantis Eyecare | Huntington Beach, California, United States | — |
| Jacobs Retina Center, UCSD | La Jolla, California, United States | — |
| Doheny Eye Center UCLA | Los Angeles, California, United States | — |
| Northern California Retina Vitreous Associates | Mountain View, California, United States | — |
| Retina Institute of California Medical Group | Palm Desert, California, United States | — |
| Byers Eye Institute, Stanford University | Palo Alto, California, United States | — |
+ 163 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04770545